Movetis – a European specialist gastrointestinal (GI) pharmaceutical company – has expanded its organisation and is now operating in the UK. Movetis (UK) Ltd aims to provide novel, innovative drugs to improve the treatment of GI diseases where currently there are only limited or inadequate treatment options available.
Movetis (UK) Ltd has built a strong team in the UK including a dedicated sales force consisting of 8 representatives who are experienced in GI disorders.
Movetis (UK) Ltd has a broad GI portfolio, with Resolor (prucalopride) as its lead product. Resolor has received EU approval and was launched in the UK in March 2010 for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Movetis (UK) Ltd aims to undertake further research with prucalopride in areas outside of its current licensed indication and advance its pipeline of GI treatments.
David Trevor, General Manager of Movetis (UK) Ltd said “The expansion of the business into the UK is an exciting time for Movetis. As a specialist GI pharmaceutical company we are able to focus our efforts and concentrate on ensuring new treatment options are made available for the management of gastrointestinal disease. The introduction of Resolor is an exciting new era for Movetis.”